Silicon Investor (SI) -- The First Internet Community

STOCKTALK

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor. We ask that you disable ad blocking while on Silicon Investor in the best interests of our community. If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.

Microcap & Penny Stocks : AMERICAN BIOMED, Minimally Invasive Technology (ABMI) -- Ignore unavailable to you. Want to Upgrade?

To: tom ablett who wrote (1197)	6/8/1998 11:23:00 PM
From: advinfo	Respond to of 2887

Northstar, If you are very long ABMI why do you insist in thrashing it's chief supporter? It really is a shame the way this thread is wasting away. Tom, Message 4778724 I'm looking forward to some more positive developments from ABMI! NorthStar

To: tom ablett who wrote (1197)	6/9/1998 11:43:00 AM
From: Jeffrey L. Henken	Read Replies (1) \| Respond to of 2887

Arterial Vascular Says Exploring 10-12 Acquisitions MINNEAPOLIS (Dow Jones)--Arterial Vascular Engineering Inc. (AVEI) President and Chief Executive Scott Solano said the company is currently exploring some 10 to 12 acquisition possibilities but declined to comment on recent speculation the company is a leading contender to buy Pfizer Inc.'s (PFE) Schneider Worldwide unit. Speaking at the Piper Jaffray investor conference here Tuesday, Solano said the 10 to 12 acquisition possibilities range from small purchases to "fairly large" ones and are in various stages of talks, including some that are just on the radar screen. The executive said the company has two components to its pricing strategy in an acquisition. He said the acquisition would have to fit strategically with the company's product line. He also said the company looks for deals that are accretive to earnings and said it isn't "shopping for dilutive" deals. If an acquisition is dilutive in the short term, it would have to be "extremely strategic," he said. "At some point at the upper end (of purchase prices), they become dilutive and they have to have a very dramatic strategic impact in order for us to assume it's okay for us to move forward with those," Solano said. "I would prefer not to be very specific regarding the exact levels of what we're looking at." As reported, Arterial Vascular could face significant earnings dilution if it completes a deal priced at more than $1.5 billion, according to observers. Shares of Arterial Vascular and Boston Scientific Corp. (BSX), believed to be another leading contender for Schneider, have slid recently on fears that a Schneider acquisition would cause short-term dilution. Boston Scientific is scheduled to present at the Piper Jaffray conference Tuesday at 1:45 p.m. Central time. -Meera Somasundaram; 612-335-8893